FDA Removes Suicide Warnings from GLP‑1 Drugs After Investigation Finds No Causal Link
The U.S. Food and Drug Administration this month requested that Novo Nordisk and Eli Lilly...
Novo Nordisk
Novo Nordisk Expands Aspect Biosystems Partnership for Diabetes Cell Therapy
Novo Nordisk (NYSE: NVO) and Canadian biotechnology firm Aspect Biosystems announced a new phase in their...
Novo Nordisk, Lilly Cut China Prices for Wegovy, Mounjaro by Up to 80%
Novo Nordisk (NYSE: NVO) and Eli Lilly (NYSE: LLY) have lowered list prices for their...
China Supreme Court Upholds Novo Nordisk Semaglutide Patent Validity
Novo Nordisk (NYSE: NVO) announced that China’s Supreme People’s Court upheld the Beijing IP Court ruling,...
Novo Nordisk’s Sogroya Wins NMPA Approval for Pediatric Growth Hormone Deficiency
Novo Nordisk (NYSE: NVO) announced that its once‑weekly long‑acting growth hormone (LAGH) injection, Sogroya (somapacitan), received...
Novo Nordisk’s Wegovy Wins China Cardiovascular Approval in Weight-Loss Market Expansion
Novo Nordisk (NYSE: NVO) announced that China’s National Medical Products Administration (NMPA) approved Wegovy (semaglutide)...
Novo Nordisk Submits CagriSema NDA for 20% Weight Loss in Obesity
Novo Nordisk A/S (NYSE: NVO) submitted a New Drug Application (NDA) to the U.S. FDA...
Novo Nordisk’s Wegovy 7.2mg Gets EMA Positive Opinion for Obesity
Novo Nordisk A/S (NYSE: NVO) announced that the European Medicines Agency’s Committee for Medicinal Products...
Novo Nordisk semaglutide Alzheimer’s biomarkers fail primary endpoint
Novo Nordisk (NYSE: NVO) reported at the Clinical Trials on Alzheimer’s Disease conference that semaglutide...
Novo Nordisk CagriSema Pediatric Obesity Trial to Enroll 460 Children
Novo Nordisk (NYSE: NVO) is planning to test its experimental obesity drug CagriSema in overweight...
Novo’s Kyinsu Wins EU Approval for Type 2 Diabetes, a Once-Weekly Combo First
Novo Nordisk A/S (NYSE: NVO) announced that the European Commission (EC) has granted marketing authorization...
Novo Nordisk’s Semaglutite Alzheimer’s Failure Sends Stock to 4-Year Low
Novo Nordisk A/S (NYSE: NVO) announced that semaglutide failed to slow disease progression in two...
Novo Nordisk Announces Major China Business Restructuring Effective Jan 1 2026
Novo Nordisk A/S (NYSE: NVO) released an internal memorandum outlining a sweeping re‑organization of its...
Novo Nordisk Rules Out Higher Bid for Metsera as Pfizer Seals $86.25 per Share Deal
Novo Nordisk A/S (NYSE: NVO) confirmed today that it will not pursue an increased offer...
Judge Rejects Pfizer’s Attempt to Block Novo Nordisk’s $10 bn Bid for Metsera
Delaware Court of Chancery Judge Morgan Zurn denied Pfizer’s (NYSE: PFE) request for a temporary...
Novo Nordisk Reports 15 % YoY Sales Growth, Cuts Full‑Year Guidance
Denmark‑based biopharma Novo Nordisk A/S (NYSE: NVO) disclosed Q1‑Q3 2025 financials that show a 15 %...
Metsera Faces Escalating Bidding War as Novo Nordisk’s $10 B Offer Tops Pfizer’s Revised Proposal
Biotech‑focused Metsera (NASDAQ: MTSR) announced that Novo Nordisk (NYSE: NVO) has submitted a “superior” acquisition...
Novo Nordisk Launches $9 Billion Unsolicited Bid for Metsera, Triggering Battle with Pfizer
Novo Nordisk A/S (NYSE: NVO) announced today an unsolicited offer of USD 9 billion for Metsera, Inc....
Novo Nordisk Board Shake‑Up: Chairman Helge Lund and Six Members Step Down After Disagreement With Foundation
Novo Nordisk A/S (NYSE: NVO) announced today that Chairman Helge Lund and six other board...